

Evaluation Form

This interactive and evidence-based program was developed by leading Canadian experts to address the importance of strict management of low density lipoprotein cholesterol (LDL-C) for patients with atherosclerotic cardiovascular disease as well as provide a timely review of the results of recently completed clinical trials and their applicability to routine clinical practice

DATE		LOCAT	ION		
			6		
Demographics					
Physician: 🖵 Yes	□ No □ Other P	lease specify			
Type of Practice:	☐ Full-time ☐ Part-time	□ Solo □ Group □ C	Office	🗅 Other	
	C. Naw Unaisana in Duali	pidemia Management in Prima	ary Care		
EARNING OBJECTIVES	a: New norizons in Dysii				
	a: New norizons in Dysii this activity, I am now be	•			
fter participating in	this activity, I am now be	tter able to:			
fter participating in 1. Discuss the role of	this activity, I am now be	t ter able to: scular risk reduction with empha	asis on the results of	recently comple	
fter participating in	this activity, I am now be LDL-C lowering in cardiova: Disagree	t ter able to: scular risk reduction with empha Neutral	Agree	recently comple	Strongly agree
fter participating in 1. Discuss the role of Strongly disagree	this activity, I am now be LDL-C lowering in cardiovas Disagree 2	t ter able to: scular risk reduction with empha	Agree 4		Strongly agree
fter participating in 1. Discuss the role of Strongly disagree 1 2. Evaluate recommen	this activity, I am now be LDL-C lowering in cardiovas Disagree 2	t ter able to: scular risk reduction with empha Neutral 3	Agree 4		Strongly agree
fter participating in 1. Discuss the role of Strongly disagree 1 2. Evaluate recommen vascular disease	this activity, I am now be LDL-C lowering in cardiovas Disagree 2 Idations for lipid lowering a	tter able to: scular risk reduction with empha Neutral 3 gents beyond or in addition to st	Agree 4 tatin therapy for patie		Strongly agree 5 sclerotic cardio
fter participating in 1. Discuss the role of Strongly disagree 1 2. Evaluate recommen vascular disease Strongly disagree	this activity, I am now being the LDL-C lowering in cardiovas Disagree 2 dations for lipid lowering a Disagree 2 disagree	tter able to: scular risk reduction with empha Neutral gents beyond or in addition to st	Agree 4 tatin therapy for patie Agree 4	ents with atheros	Strongly agree 5 sclerotic cardio Strongly agree 5
fter participating in 1. Discuss the role of Strongly disagree 2. Evaluate recommen vascular disease Strongly disagree 1 3. Explain the mechani	this activity, I am now being the LDL-C lowering in cardiovas Disagree 2 dations for lipid lowering a Disagree 2 disagree	tter able to: scular risk reduction with empha Neutral gents beyond or in addition to st Neutral 3	Agree 4 tatin therapy for patie Agree 4	ents with atheros	Strongly agree 5 sclerotic cardio Strongly agree 5
fter participating in 1. Discuss the role of Strongly disagree 2. Evaluate recommen vascular disease Strongly disagree 1 3. Explain the mechani to patient managen	this activity, I am now being the LDL-C lowering in cardiovas Disagree 2 dations for lipid lowering a Disagree 2 dism of action of proprotein nent strategies	tter able to: scular risk reduction with empha Neutral gents beyond or in addition to st Neutral 3 convertase subtilisin/kexin type	Agree 4 tatin therapy for patie Agree 4 2 9 (PCSK9) inhibitors	ents with atheros	Strongly agree 5 sclerotic cardio Strongly agree 5 stest clinical data
fter participating in 1. Discuss the role of Strongly disagree 1. Evaluate recommen vascular disease Strongly disagree 1. Explain the mechani to patient managen Strongly disagree	this activity, I am now be to LDL-C lowering in cardiovas Disagree 2 dations for lipid lowering a Disagree 2 cism of action of proproteinment strategies Disagree 2	tter able to: scular risk reduction with empha Neutral gents beyond or in addition to st Neutral convertase subtilisin/kexin type	Agree tatin therapy for patie Agree 4 9 (PCSK9) inhibitors Agree 4	ents with atheros	Strongly agree Strongly agree Strongly agree Strongly agree Strongly agree Strongly agree
fter participating in 1. Discuss the role of Strongly disagree 1. Evaluate recommen vascular disease Strongly disagree 1. Explain the mechani to patient managen Strongly disagree	this activity, I am now be to LDL-C lowering in cardiovas Disagree 2 dations for lipid lowering a Disagree 2 cism of action of proproteinment strategies Disagree 2	tter able to: scular risk reduction with empha Neutral gents beyond or in addition to st Neutral 3 convertase subtilisin/kexin type Neutral 3	Agree tatin therapy for patie Agree 4 9 (PCSK9) inhibitors Agree 4	ents with atheros	Strongly agree Strongly agree Strongly agree Strongly agree Strongly agree Strongly agree

abetes & Cardiovascular Disease

d session, participants will be able to:

es for risk of macro and microvascular disease

sagi	ree	Neutral Neutral				Agree
2		3				
ect	ion for yo	ur patients	with diabeto	es		
sagree			Neutral			Agree
2			3			4
oies	s to help r	each the LO	OL-C target			
sagi	ree		Neutral			Agree
2		Case 2 - LOL-C: How Low				4
		s case based session, parti Dyslipidemia guidelines to cl				
	Strongly disagree	Disagree 2	Neutral 3 and select the appropriate thera	Agree 4	Strongly agree 5	
	Strongly disagree	Disagree	Neutral	Agree	Strongly agree	
	3. Explain the evidence a	2 nd safety data for achieving ver	ry low LDL-C levels	4	5	
	Strongly disagree	Disagree	Neutral	Agree	Strongly agree	
	1	2	3	4	5	
	LEARNING OBJECTIVES:	Case 4 - Familial Hyperch	olesterolemia			
	1. Review the diagnost	ic criteria for Familial Hypero	holesterolemia			
	Strongly disagree	Disagree	Neutral	Agree	Strongly agree	
	7 Apply the pouls appe	2 osed Canadian definition of Fa	3	4	5	
	2. Apply the newly prop Strongly disagree	useu Ganadian deminidum of Fa Disagree	Neutral	Agrag	Strongly agree	
	l I	2	3	Agree 4	5	
	3. Employ evidence-base	d recommendations to LDL-C ta	rgets in this population			
	Strongly disagree	Disagree	Neutral	Agree	Strongly agree	
	1	2	3	4	5	

Upon completion of this cas	e based session, participan	ts will be able to:				
1. Identify patients with ASC\	VD and with multiple CV risk f	actors and those who hav	e especially higl	n risk features (eg:	: PAD)	
Strongly disagree	Disagree	Neutral	Agre	е	Strongly agree	
1	2	3	4		5	
2. Prioritize treatment option	ns in alignment with patient p	riorities				
Strongly disagree	Disagree	Neutral	Agre	е	Strongly agree	_
1	2	3	4		5	
3. Identify circumstances requ	iring use of statin-add-on thera	pies to achieve goal				
Strongly disagree	Disagree	Neutral	Agre	е	Strongly agree	_
1	2	3	4		5	
4. Review safety and efficacy o	f PCSK9 inhibitors in specific hi	gh risk populations				
Strongly disagree	Disagree	Neutral	Agre	е	Strongly agree	_
1	2	3	4		5	
5. Discuss safety and CV risk r	eduction benefits of very low LC	JL-C goals				
Strongly disagree	Disagree	Neutral	Agre	9	Strongly agree	_
1	2	3	4		5	
Was effective in Pre	sp1 esenting Material:					
Strongly disagree	Disagree	Neutral		Agree		Strongly agree
1	2	3		4		5
Did you perceive an	y degree of bias in any par	rt of the program?	☐ Yes	□ No		
If so, please explain:						
Speaker	ps2					
Was effective in Pre	esenting Material:					
Strongly disagree	Disagree	Neutral		Agree		Strongly agree
1	2	3		4		5
Did you perceive an	y degree of bias in any par	rt of the program?	□ Yes	□ No		
If so, please explain:						
п ъи, рівазе вхрівіїї: —						

LEARNING OBJECTIVES: Case 3 - ASCVD with Multiple CV Risk Factors

This Program	Please indicate with CAnMEDS roles you felt were addressed during this educational activity.				
Content enhanced my knowledge					
Strongly disagree Neutral Strongly agree	☐ Family Medicine Expert				
Addressed my most pressing questions	☐ Collaborator				
Strongly disagree Neutral Strongly agree	☐ Communicator				
1 2 3 4 5	☐ Manager				
Promoted improvements or quality in health care	☐ Health Advocate				
Strongly disagree Neutral Strongly agree	□ Professional				
Was scientifically rigorous and evidence-based					
Strongly disagree Neutral Strongly agree	☐ Scholar				
1 2 3 4 5					
Provided appropriate and effective opportunities for active learning (ie., case studies, discussion, Q GA, etc)					
Strongly disagree Neutral Strongly agree					
1 2 3 4 5					
Provided an opportunity for interaction with my peers Stronoly disagree Neutral Stronoly agree					
Strongly disagree Neutral Strongly agree					
Based on your participation in this program, please select all applicable statement(s): I gained new strategies/skills/information that I can apply to my area of practice. I plan to implement new strategies/skills/information into my practice. I need more information before I can implement new strategies/skills/information into my practice behavior This program will not change my practice, as my current practice is consistent with the information presented. This program will not change my practice, as I do not agree with the information presented. What strategies/changes do you plan to implement into your practice?					
What barriers do you see to making a change in your practice? Future Topics of Interest / Additional Comment & Suggestions					
Thank you for your feedback!					